Cancer immunoediting from immune surveillance to immune escape

被引:787
作者
Kim, Ryungsa [1 ]
Emi, Manabu
Tanabe, Kazuaki
机构
[1] Hiroshima Univ, Int Radiat Informat Ctr, Res Inst Radiat Biol & Med, Hiroshima 724, Japan
[2] Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima 724, Japan
关键词
cancer; immune escape; immune surveillance; immunoediting;
D O I
10.1111/j.1365-2567.2007.02587.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction of host and tumour cells, three essential phases have been proposed: elimination, equilibrium and escape, which are designated the 'three E's'. Several immune effector cells and secreted cytokines play a critical role in pursuing each process. Nascent transformed cells can initially be eliminated by an innate immune response such as by natural killer cells. During tumour progression, even though an adaptive immune response can be provoked by antigen-specific T cells, immune selection produces tumour cell variants that lose major histocompatibility complex class I and II antigens and decreases amounts of tumour antigens in the equilibrium phase. Furthermore, tumour-derived soluble factors facilitate the escape from immune attack, allowing progression and metastasis. In this review, the central roles of effector cells and cytokines in tumour immunity, and the escape mechanisms of tumour cells during tumour progression are discussed.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 130 条
[71]  
Naito Y, 1998, CANCER RES, V58, P3491
[72]   Immune surveillance against a solid tumor fails because of immunological ignorance [J].
Ochsenbein, AF ;
Klenerman, P ;
Karrer, U ;
Ludewig, B ;
Pericin, M ;
Hengartner, H ;
Zinkernagel, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2233-2238
[73]   Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex [J].
Ohashi, K ;
Burkart, V ;
Flohé, S ;
Kolb, H .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :558-561
[74]   IMMUNOLOGY OF EXPERIMENTAL TUMORS [J].
OLD, LJ ;
BOYSE, EA .
ANNUAL REVIEW OF MEDICINE, 1964, 15 :167-&
[75]  
Oyama T, 1998, J IMMUNOL, V160, P1224
[76]   Solid tumors after heart transplantation: Lethality of lung cancer [J].
Pham, SM ;
Kormos, RL ;
Landreneau, RJ ;
Kawai, A ;
GonzalezCancel, I ;
Hardesty, RL ;
Hattler, BG ;
Griffith, BP .
ANNALS OF THORACIC SURGERY, 1995, 60 (06) :1623-1626
[77]  
Pietras K, 2001, CANCER RES, V61, P2929
[78]   Threat matrix - Low-molecular-weight hyaluronan (HA) as a danger signal [J].
Powell, JD ;
Horton, MR .
IMMUNOLOGIC RESEARCH, 2005, 31 (03) :207-218
[79]  
PREHN RT, 1957, J NATL CANCER I, V18, P769
[80]   CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells [J].
Qin, ZH ;
Blankenstein, T .
IMMUNITY, 2000, 12 (06) :677-686